Orion sues Wockhardt Over Parkinson's Drug
Orion announced that it filed the suit late Thursday, over the defendants' efforts to obtain regulatory approval for generic 200 milligram entacapone tablets. Entacapone is the active ingredient in Comtan, which is marketed in the U.S. by Novartis.
“Orion Corporation and Novartis will vigorously defend the intellectual property rights covering Comtan,”...
To view the full article, register now.